THALES
8.12.2021 08:02:06 CET | Business Wire | Press release
Gireve, the leading B2B digital platform for electric mobility, and Thales, leader in digital security, have collaborated to provide a simple and secure ´Plug & Charge´ access and billing system. The joint solution, based on the Thales Trusted Key Manager and Gireve’s intermediation platform, improves the driver experience, builds trust in a multi players’ ecosystem and also helps meet the ISO 15118 International standard.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207006154/en/
While the EV market rapidly expands, convenient access to charging networks becomes a priority. The current charging network is still very fragmented, often proprietary and not available in enough places. A global standardized and interoperable solution is needed as well as an improved management of the delivery of electricity.
Today each e-Mobility Service Provider (eMSP) offers EV drivers an RFID card to access and start a charging session. Gireve and Thales have partnered to create a harmonized ´Plug & Charge´ solution to simplify the experience and ensure the highest level of security for all EV market players.
Drivers simply plug their electric car into any ISO 15118-compatible charging station, without using a physical card, and the billing is automatically associated to the subscription managed for them. As a result drivers can then freely choose an e-Mobility Service Provider and access a wider number of charging stations; while benefitting from a secure automated charging and digital payment experience.
The solution delivers unique credential certificates to each actor in the system from driver to vehicle and charging station. The system, based on Thales Trusted Key Manager then ensures the secure and instant mutual authentication between these actors. The solution also verifies that the right credentials are securely generated and distributed from the right e-Mobility Provider to the associated vehicle and user. The result – a simpler and more secure EV charging experience.
This mutual authentication and secure credentials management also set the basis of a trusted environment for coming smart grid deployments. As the EV market is expected to boom in the coming years, so does electricity need. Indeed, such increasing needs will require improved and safe energy management and delivery to address power peaks demand.
“ For almost 10 years, Gireve has been a central trusted third party for B2B players in the charging sector. Together with Thales, we are confident our solution addresses key challenges to back up the sustainable success of the EV ecosystem. Our joint efforts are all about facilitating energy access, bringing trust through cybersecurity and boosting drivers’ adoption with improved usage.” Eric Plaquet, CEO at Gireve
“Gireve offered Thales a great opportunity to deploy its field-proven expertise in strong authentication and cybersecurity to the smart charging market. Our partnership supports the sustainable e-mobility sector, by smoothing EV charging access and by creating the trust the sector needs to succeed. Looking forward, our collaboration may unleash further use cases to support smart grid development with more efficient energy management.” Christine Caviglioli, Vice President Automotive at Thales
1
https://www.delta-ee.com/downloads/1-research-downloads/2830-whitepaper-ev-forecasts-84-million-evs-on-european-roads-by-2030.html
2
ISO 15118 is an international standard that outlines the digital communication protocol that an electric vehicle (EV) and charging station should use to recharge the EV’s high-voltage battery.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
About GIREVE
Combining Market Place, Transactions Processing, and Data Management technologies, GIREVE is the leading B-to-B digital platform for electric recharging, offering the first coverage in terms of number of charge points in Europe. The company manages 3,800 contracts between 277 players in 32 countries and references more than 220,000 charge points, including 149,000 open to roaming.
For almost 10 years, GIREVE has been a central trusted third party for B-to-B players in the charging sector, handling negotiations and transactions independently, securely, according to transparent rules, and in compliance with regulations.
PLEASE VISIT
Thales Group
Market page
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207006154/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
